Adopting New Approaches in AL Amyloidosis: Expert Perspectives on Latest Evidence

Join us for a live, CME-certified 1.5 hour webinar to gain expert insights on managing newly diagnosed and relapsed AL amyloidosis. Experts will answer audience questions. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

Welcome, Introduction, and Baseline Outcomes Assessment

Classification, diagnosis, staging, and response assessment

  • Differentiation in diagnosis of amyloidosis; organ involvement
  • Clinical manifestations, diagnostic imaging approaches in amyloidosis, algorithm for evaluating patients with suspected amyloidosis, recommended staging systems
  • Treatment response assessment; hematologic/organ response criteria

Initial management of AL amyloidosis

  • Current/evolving management algorithm for the newly diagnosed AL amyloidosis patient
    • Impact of recent FDA approvals
  • Transplant

Management of AL amyloidosis at relapse

  • Current/evolving algorithm for the management of AL amyloidosis at relapse

Supportive management in AL amyloidosis

Conclusion

  • Summary, Final Thoughts, and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Faculty
Ankit Kansagra, MD

Eugene P. Frenkel MD Scholar of Clinical Medicine
Assistant Professor of Medicine
Division of Hematology/Oncology
University Texas Southwestern Medical Center
Dallas, Texas

Faculty
Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair,
 Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Faculty
Vaishali Sanchorawala, MD

Professor of Medicine
Director, Amyloidosis Center
Boston University School of Medicine
Director, Autologous Stem Cell Transplantation Program
Section of Hematology-Oncology
Boston Medical Center
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare professionals to confidently and competently integrate currently available and novel regimens to treat newly diagnosed and relapsed/refractory AL amyloidosis into their clinical practices.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with AL amyloidosis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Recognize and diagnose AL amyloidosis through timely and accurate typing of the precursor protein to guide specific management approaches
  • Integrate into practice up-to-date efficacy and safety data on currently available and novel regimens to treat newly diagnosed and relapsed/refractory AL amyloidosis based on accurate risk and response assessment
  • Based on the current best evidence, implement supportive therapy in AL amyloidosis to improve quality of life, relieving symptom, and sustain organ function
  • Appraise ongoing clinical trials evaluating novel therapy for the treatment of patients with AL amyloidosis

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - XXXX

Type of Activity: XXX

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.